Turbulent times for hormone replacement therapy: Is there a way out?

Gynecologic and Obstetric Investigation

Volumn 56, Issue 1, 2003, Pages 43-50

  Verhaeghe, Johan ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Androgen insufficiency; Estrogen insufficiency; Hormone replacement therapy; Menopause; Ovarian hormone insufficiency syndrome

Indexed keywords

ANDROGEN; CONJUGATED ESTROGEN; ESTROGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ARTICLE; BLEEDING; BREAST CANCER; BREAST DISEASE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; ENDOCRINE DISEASE; ENDOMETRIUM CANCER; ESTROGEN BLOOD LEVEL; GALLBLADDER DISEASE; HEALTH SURVEY; HORMONE SUBSTITUTION; HUMAN; MEDICAL RESEARCH; MENOPAUSAL SYNDROME; MENOPAUSE; METHODOLOGY; OVARIAN HORMONE INSUFFICIENCY SYNDROME; OVARY CANCER; RISK ASSESSMENT; THROMBOEMBOLISM;

AGED; ANDROGENS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; PROGESTINS; RANDOMIZED CONTROLLED TRIALS; WOMEN'S HEALTH;

EID: 0042925331     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072483     Document Type: Article

References (54)

1. Enserink M: The vanishing promises of hormone replacement therapy. Science 2002;297:325-326.
2. Grodstein F, Stampfer MJ, Colditz GA, et al: Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-1775.
3. Yaffe K, Sawaya G, Lieberburg I, Grady D: Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia. JAMA 1998;279:688-695.
4. Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH: Effects of lower doses of conjugated estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080-1087.
5. Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S, Barrett-Connor E: Symptom relief and side effects of postmenopausal hormones: Results from the Postmenopausal Estrogen/Progestin Interventions trial. Obstet Gynecol 1998;92:982-988.
6. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G: Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-37.
7. Miller J, Chan BKS, Nelson HD: Postmenopausal estrogen replacement and risk for venous thromboembolism: A systematic review and meta-analysis for the US Preventive Task Force. Ann Intern Med 2002;136:680-690.
8. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet 1995;346:1575-1582.
9. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS). JAMA 1998;280:605-613.
10. Grady D, Herrington D, Bittner V, et al: Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
11. Hulley S, Furberg C, Barrett-Connor E, et al: Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
12. Herrington DM, Reboussin DM, Brosnihan B, et al: Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.
13. Cherry N, Gilmour K, Hannaford P, et al, ESPRIT team: Oestrogen therapy for prevention of reinfarction in postmenopausal women: A randomised placebo controlled trial. Lancet 2002;360:2001-2008.
14. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Pettiti D: Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-313.
15. Beresford SAA, Weiss NS, Voigt LF, McKnight B: Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-461.
16. Weiderpass E, Baron JA, Adami H-O, et al: Low-potency oestrogen and risk of endometrial cancer: A case-control study. Lancet 1999;353:1824-1828.
17. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-1059.
18. Colditz GA, Hankinson SE, Hunter DJ, et al: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
19. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491.
20. Nanda K, Bastian LA, Schulz K: Hormone replacement therapy and the risk of death from breast cancer: A systematic review. Am J Obstet Gynecol 2002;186:325-334.
21. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
22. Cranney A, Guyatt G, Griffith L, et al: Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analysis of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-578.
23. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al: Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: A randomized trial. JAMA 2003;289:2673-2684.
24. Beral V, Banks E, Reeves G: Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-944.
25. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ: A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941.
26. Grodstein F, Clarkson TB, Manson JE: Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-650.
27. Hodis HN, Mack WJ, Lobo RA, et al: Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-953.
28. Decensi A, Omodei U, Robertson C, et al: Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002;106:1224-1228.
29. Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208. Erratum in JAMA 1995;274:1676.
30. US Preventive Services Task Force: Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: Recommendations and rationale. Ann Intern Med 2002;137:834-839.
31. North American Menopause Society: Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. Menopause 2003;10:6-12.
32. Greendale GA, Espeland M, Slone S, Marcus R, Barrett-Connor E: Bone mass response to discontinuation of long-term hormone replacement therapy: Results from the Postmenopausal Estrogens/Progestin Interventions (PEPI) safety follow-up study. Arch Intern Med 2002;162:665-672.
33. Greenspan SL, Emkey RD, Bone HG, et al: Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:875-883.
34. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR: Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9-16.
35. US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: Recommendations and rationale. Ann Intern Med 2002;137:526-528.
36. Siris ES, Miller PD, Barrett-Connor E, et al: Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. Results from the National Osteoporosis Risk Assessment. JAMA 2001;286:2815-2822.
37. Prior JC: Perimenopause: The complex endocrinology of the menopausal transition. Endocr Rev 1998;19:397-428.
38. Bachmann G, Bancroft J, Braunstein G, et al: Female androgen insufficiency: The Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002;77:660-665.
39. Kravitz HM, Ganz PA, Bromberger J, Powell LH, Sutton-Tyrrell K, Meyer PM: Sleep difficulty in women at midlife: A community survey of sleep and the menopausal transition. Menopause 2003;10:19-28.
40. Polo-Kantola P, Erkkola R, Irjala K, Pullinen S, Virtanen I, Polo O: Effect of short-term transdermal estrogen replacement therapy on sleep: A randomized, double-blind crossover trial in postmenopausal women. Fertil Steril 1999;71:873-880.
41. Joffe H, Hall JE, Soares CN, Hennen J, Reilly CJ, Carlson K, Cohen LS: Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 2002;9:392-398.
42. Warnock JK, Bundren JC, Morris DW: Depressive mood symptoms associated with ovarian suppression. Fertil Steril 2000;74:984-986.
43. Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, Rubinow DR: Estrogen replacement in perimenopause-related depression: A preliminary report. Am J Obstet Gynecol 2000;183:414-420.
44. Rapp SR, Espeland MA, Shumaker SA, et al: Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003;289:2663-2672.
45. Shumaker SA, Legault C, Rapp SR, et al: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003;289:2651-2662.
46. Sherwin BB: Estrogen and cognitive functioning in women. Endocr Rev 2003;24:133-151.
47. Shaywitz SE, Shaywitz BA, Pugh KR, et al: Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1999;281:1197-1202.
48. Yaffe K, Lui L-Y, Grady D, Stone K, Morin P: Estrogen receptor 1 polymorphisms and risk of cognitive impairment in older women. Biol Psychiatry 2002;51:677-682.
49. Hays J, Ockene JK, Brunner RL, et al: Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-1854.
50. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH: Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1079.
51. Shifren JL, Braunstein GD, Simon JA, et al: Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-688.
52. Modelska K, Cummings S. Tibolone for postmenopausal women: Systematic review of randomized trials. J Clin Endocrinol Metab 2002;87:16-23.
53. Huber J, Palacios S, Berglund L, Hänggi W, Sathanandan SM, Christau S, Helmond F: Effects of tibolone and continuous combined hormone replacement therapy, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaecol 2002;109:886-893.
54. Landgren MB, Coelingh Bennink HJT, Helmond FA, Engelen S: Dose-response analysis of effects of tibolone on climacteric symptoms. Br J Obstet Gynaecol 2002;109:1109-1114.